Clinical support for such observations comes from medical interventions to reduce circulating levels of thyroid hormone [23, 72], from effects of hypothyroidism secondary to tyrosine kinase inhibitor use in patients with renal cell carcinoma [73, 74] and from the effects of spontaneous hypothyroidism on the clinical behavior of breast cancer [75]. The gene discussed is TG; the disease is breast cancer.